Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Sells 2,937 Shares of Stock

Key Points

• Denali Therapeutics insider Alexander O. Schuth sold 2,937 shares at an average price of $13.58, resulting in a total transaction value of $39,884.46, reducing their ownership by 1.20%.
• Denali Therapeutics stock experienced a decline of 2.4%, closing at $14.46, with analysts forecasting a -2.71 EPS for the current fiscal year.
• Research analysts have mixed ratings on Denali Therapeutics, with a consensus target price averaging $33.85, highlighting a strong buy sentiment among multiple analysts.

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Alexander O. Schuth sold 2,937 shares of Denali Therapeutics stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the transaction, the insider directly owned 242,346 shares of the company's stock, valued at approximately $3,291,058.68. This trade represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Denali Therapeutics Stock Down 2.4%

Shares of NASDAQ DNLI traded down $0.35 on Thursday, reaching $14.46. 1,767,093 shares of the company's stock traded hands, compared to its average volume of 1,717,922. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $33.33. The business's 50 day simple moving average is $14.30 and its two-hundred day simple moving average is $15.42. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -5.16 and a beta of 1.36. The company has a quick ratio of 9.56, a current ratio of 10.27 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same quarter in the prior year, the company posted ($0.59) EPS. As a group, equities research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DNLI has been the subject of a number of research analyst reports. HC Wainwright decreased their target price on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Bank of America dropped their price objective on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. TD Cowen upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. Finally, Wedbush dropped their target price on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $33.85.

Institutional Investors Weigh In On Denali Therapeutics

A number of hedge funds have recently modified their holdings of DNLI. Mirae Asset Global Investments Co. Ltd. grew its stake in Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company's stock worth $79,000 after acquiring an additional 753 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Denali Therapeutics by 7.4% during the second quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company's stock valued at $189,000 after purchasing an additional 930 shares in the last quarter. Knights of Columbus Asset Advisors LLC boosted its stake in shares of Denali Therapeutics by 2.7% during the first quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company's stock valued at $548,000 after purchasing an additional 1,058 shares in the last quarter. Sterling Capital Management LLC boosted its stake in Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after acquiring an additional 1,516 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Denali Therapeutics by 277.0% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after acquiring an additional 1,551 shares in the last quarter. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.